The estimated Net Worth of Richard Christopher is at least $679 Tisíc dollars as of 10 March 2020. Mr. Christopher owns over 3,636 units of InVivo Therapeutics Corp stock worth over $1,670 and over the last 8 years he sold NVIV stock worth over $0. In addition, he makes $677,710 as Chief Financial Officer at InVivo Therapeutics Corp.
Richard has made over 1 trades of the InVivo Therapeutics Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 3,636 units of NVIV stock worth $1,164 on 10 March 2020.
The largest trade he's ever made was buying 3,636 units of InVivo Therapeutics Corp stock on 10 March 2020 worth over $1,164. On average, Richard trades about 303 units every 0 days since 2016. As of 10 March 2020 he still owns at least 5,220 units of InVivo Therapeutics Corp stock.
You can see the complete history of Mr. Christopher stock trades at the bottom of the page.
Richard C. Christopher serves as Chief Financial Officer of the Company. Mr. Christopher was the Chief Financial Officer of iCAD, Inc. from December 2016 through January 2019. iCAD, Inc. is a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer from March 2014 through December 2016 and Chief Operating Officer from October 2015 through December 2016 of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Prior to Caliber and starting in 2000, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a Nasdaq-listed dermatology company focused on the treatment of precancerous skin lesions, where he ultimately served as Chief Financial Officer from January 2005 through its acquisition and integration into Sun Pharmaceuticals Industries Ltd in April 2013. Mr. Christopher holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Finance from Bentley University.
As the Chief Financial Officer of InVivo Therapeutics Corp, the total compensation of Richard Christopher at InVivo Therapeutics Corp is $677,710. There are 2 executives at InVivo Therapeutics Corp getting paid more, with Richard Toselli having the highest compensation of $1,257,090.
Richard Christopher is 50, he's been the Chief Financial Officer of InVivo Therapeutics Corp since 2019. There are 11 older and no younger executives at InVivo Therapeutics Corp. The oldest executive at InVivo Therapeutics Holdings Corp is Richard Roberts, 76, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O INVIVO THERAPEUTICS HOLDINGS CORP., ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE, MA, 02139.
Over the last 14 years, insiders at InVivo Therapeutics Corp have traded over $11,891,061 worth of InVivo Therapeutics Corp stock and bought 364,908 units worth $191,940 . The most active insiders traders include Francis Reynolds, Robert Langer a Sean F. Moran. On average, InVivo Therapeutics Corp executives and independent directors trade stock every 24 days with the average trade being worth of $10,438. The most recent stock trade was executed by Brice Foose on 5 February 2023, trading 330,000 units of NVIV stock currently worth $122,100.
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi
InVivo Therapeutics Corp executives and other stock owners filed with the SEC include: